SELLAS Life Sciences Gr Stock (NASDAQ: SLS)

SELLAS Life Sciences Gr

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

movers

News

Intraday Update

Markets

Movers

Trading Ideas

AGRI

ALLG

AMCX

ATRA

AVTE

BIMI

BJDX

BMEA

BTDR

CETX

CNSP

EVTV

FCEL

FLFV

KAVL

LRHC

LXRX

MBIO

MEDS

MIRM

MYTE

NDRA

OUST

OVID

PRMW

SCNI

SCPX

SPCE

SYNX

TRNR

VERO

WKHS

XPOF

XTLB

XXII

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Biotech

Earnings

Penny Stocks

Upgrades

Analyst Ratings

General

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

Galena Biopharma Upgraded to Buy: Here&#39;s What You Should Know

Eurozone

Commodities

Small Cap

Global

ADBE

CDLX

CISS

IMRX

VERB

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday.

The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&amp;P 500 also fell, dropping, 0.64% to 5,117.35.

Dow Falls Over 200 Points; Adobe Shares Plunge

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Group Inc

Solasto Corp

SELECT SANDS CORP ORD by Select Sands Corp.

Select Sands Corp

Solaris Resources Inc

Solaris Resources Inc Ordinary Shares

Press Releases

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Health Care

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

SELLAS Announces Key Business Objectives for 2025

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Opinion

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

AMGN

CELC

GNTA

ONCY

TSX:ONC

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Cabaletta Bio

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Citius Oncology

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

HilleVax

TuHURA Biosciences

IGM Biosciences

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lexeo Therapeutics

PepGen

Regulus Therapeutics

Skye Bioscience

Vigil Neuroscience

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Cantor Fitzgerald

Alliance Global Partners

SELLAS Life Sciences

Comments

SELLAS Life Sciences Gr

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga